Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.56 |
| ▸ | CA2 | P00918 | 7/20 | 0.56 |
| ▸ | CA12 | O43570 | 6/20 | 0.56 |
| ▸ | CA9 | Q16790 | 6/20 | 0.56 |
| ▸ | CA3 | P07451 | 6/20 | 0.56 |
| ▸ | CA6 | P23280 | 6/20 | 0.56 |
| ▸ | CA7 | P43166 | 6/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 6/20 | 0.56 |
| ▸ | CA4 | P22748 | 5/20 | 0.56 |
| ▸ | CA13 | Q8N1Q1 | 5/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 5/20 | 0.56 |
| ▸ | CA5A | P35218 | 3/20 | 0.56 |
| ▸ | CISD1 | Q9NZ45 | 1/20 | 0.44 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31704495 | 0.80 | CA12 (0.51) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3342235 | 0.78 | CA12 (0.46) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3342014 | 0.75 | CA1 (0.46) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3341637 | 0.75 | CA12 (0.38) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3342573 | 0.74 | LCK (0.47) | — | |
| SCHEMBL3341117 | 0.74 | CA12 (0.43) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3341566 | 0.73 | CA1 (0.40) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3342762 | 0.73 | CA1 (0.40) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3340033 | 0.73 | CA1 (0.40) | CA1CA2CA12CA9CA3 | |
| SCHEMBL3339243 | 0.73 | CA12 (0.46) | CA1CA2CA12CA9CA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2393781-B1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | HOFFMANN LA ROCHE (CH) | 2014-03-12 | — | — | EP | disclosed |
| EP-2393781-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. Hoffmann-La Roche AG (CH) | 2011-12-14 | — | — | EP | disclosed |
| WO-2010072599-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2010-07-01 | — | — | WO | disclosed |
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | ROCHE PALO ALTO LLC | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160388-A1 | DIHYDROPYRIDONE UREAS AS P2X7 MODULATORS | P2RY1, P2RX1, P2RX3 | CA1 4329/4885CA2 3152/4885CA12 4856/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.